RU2009120724A - Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она - Google Patents
Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она Download PDFInfo
- Publication number
- RU2009120724A RU2009120724A RU2009120724/04A RU2009120724A RU2009120724A RU 2009120724 A RU2009120724 A RU 2009120724A RU 2009120724/04 A RU2009120724/04 A RU 2009120724/04A RU 2009120724 A RU2009120724 A RU 2009120724A RU 2009120724 A RU2009120724 A RU 2009120724A
- Authority
- RU
- Russia
- Prior art keywords
- fumarate salt
- fumarate
- drugs
- formula
- drug
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 29
- 229940079593 drug Drugs 0.000 claims abstract 22
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 10
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 6
- 208000019022 Mood disease Diseases 0.000 claims abstract 6
- 230000002920 convulsive effect Effects 0.000 claims abstract 6
- 238000002360 preparation method Methods 0.000 claims abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 7
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 5
- 239000012458 free base Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000011084 recovery Methods 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- ALQXIMVNPRVWQA-UHFFFAOYSA-N 3-benzyl-2-methyl-3,3a,5,6,7,7a-hexahydro-1,2-benzoxazol-4-one Chemical compound CN1OC2CCCC(=O)C2C1CC1=CC=CC=C1 ALQXIMVNPRVWQA-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- ALQXIMVNPRVWQA-VHDGCEQUSA-N (3r,3as,7as)-3-benzyl-2-methyl-3,3a,5,6,7,7a-hexahydro-1,2-benzoxazol-4-one Chemical compound C([C@@H]1[C@@H]2C(=O)CCC[C@@H]2ON1C)C1=CC=CC=C1 ALQXIMVNPRVWQA-VHDGCEQUSA-N 0.000 claims 1
- JGRCHNVLXORPNM-UHFFFAOYSA-N 1,2-oxazol-4-one Chemical compound O=C1CON=C1 JGRCHNVLXORPNM-UHFFFAOYSA-N 0.000 claims 1
- VDMIUPXZVFBGTC-WLHGVMLRSA-N 3-benzyl-2-methyl-3,3a,5,6,7,7a-hexahydro-1,2-benzoxazol-4-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CN1OC2CCCC(=O)C2C1CC1=CC=CC=C1 VDMIUPXZVFBGTC-WLHGVMLRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002102A ITMI20062102A1 (it) | 2006-11-02 | 2006-11-02 | Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one |
| ITMI2006A002102 | 2006-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009120724A true RU2009120724A (ru) | 2010-12-10 |
Family
ID=39145485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120724/04A RU2009120724A (ru) | 2006-11-02 | 2007-10-31 | Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она |
| RU2009120667/04A RU2009120667A (ru) | 2006-11-02 | 2007-10-31 | Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120667/04A RU2009120667A (ru) | 2006-11-02 | 2007-10-31 | Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100069450A1 (enExample) |
| EP (2) | EP2094674B1 (enExample) |
| JP (2) | JP2010509309A (enExample) |
| KR (2) | KR20090082452A (enExample) |
| CN (2) | CN101535281A (enExample) |
| AT (2) | ATE502021T1 (enExample) |
| AU (2) | AU2007315832A1 (enExample) |
| BR (2) | BRPI0718392A2 (enExample) |
| CA (2) | CA2667515A1 (enExample) |
| DE (2) | DE602007013278D1 (enExample) |
| HR (2) | HRP20090477A2 (enExample) |
| IL (2) | IL198443A0 (enExample) |
| IT (1) | ITMI20062102A1 (enExample) |
| MX (2) | MX2009004294A (enExample) |
| NO (2) | NO20092115L (enExample) |
| NZ (2) | NZ577978A (enExample) |
| RS (2) | RS20090389A (enExample) |
| RU (2) | RU2009120724A (enExample) |
| WO (2) | WO2008053326A1 (enExample) |
| ZA (2) | ZA200903618B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2112142A1 (en) * | 2008-04-24 | 2009-10-28 | Abiogen Pharma S.p.A. | Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
| EP2218721A1 (en) * | 2009-02-11 | 2010-08-18 | LEK Pharmaceuticals d.d. | Novel salts of sitagliptin |
| WO2011010332A1 (en) * | 2009-07-23 | 2011-01-27 | Abiogen Pharma S.P.A. | Process for preparing rel-(3r*,3as*,7as*)-3-benzyl-2-methyl-2,3, 3a,4,5,6,7,7a- octahydrobenzo[d]isoxazoi-4-one or a salt thereof |
| US10131642B1 (en) * | 2015-01-30 | 2018-11-20 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161595A (en) * | 1978-10-02 | 1979-07-17 | Bristol-Myers Company | Levulinic acid salt |
| US4419358A (en) * | 1981-11-12 | 1983-12-06 | Mead Johnson & Company | Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it |
| GB2264299B (en) * | 1992-02-19 | 1995-07-26 | British Tech Group | Iso-oxazolidine derivatives |
-
2006
- 2006-11-02 IT IT002102A patent/ITMI20062102A1/it unknown
-
2007
- 2007-10-31 KR KR1020097011322A patent/KR20090082452A/ko not_active Withdrawn
- 2007-10-31 CA CA002667515A patent/CA2667515A1/en not_active Abandoned
- 2007-10-31 DE DE602007013278T patent/DE602007013278D1/de active Active
- 2007-10-31 WO PCT/IB2007/003292 patent/WO2008053326A1/en not_active Ceased
- 2007-10-31 JP JP2009535824A patent/JP2010509309A/ja active Pending
- 2007-10-31 CN CNA2007800406598A patent/CN101535281A/zh active Pending
- 2007-10-31 AT AT07825549T patent/ATE502021T1/de not_active IP Right Cessation
- 2007-10-31 RS RSP-2009/0389A patent/RS20090389A/sr unknown
- 2007-10-31 AU AU2007315832A patent/AU2007315832A1/en not_active Abandoned
- 2007-10-31 RU RU2009120724/04A patent/RU2009120724A/ru not_active Application Discontinuation
- 2007-10-31 MX MX2009004294A patent/MX2009004294A/es not_active Application Discontinuation
- 2007-10-31 US US12/513,351 patent/US20100069450A1/en not_active Abandoned
- 2007-10-31 CN CNA2007800406691A patent/CN101535282A/zh active Pending
- 2007-10-31 EP EP07825549A patent/EP2094674B1/en not_active Not-in-force
- 2007-10-31 BR BRPI0718392-5A patent/BRPI0718392A2/pt not_active IP Right Cessation
- 2007-10-31 HR HR20090477A patent/HRP20090477A2/hr not_active Application Discontinuation
- 2007-10-31 RU RU2009120667/04A patent/RU2009120667A/ru not_active Application Discontinuation
- 2007-10-31 MX MX2009004293A patent/MX2009004293A/es not_active Application Discontinuation
- 2007-10-31 AU AU2007315833A patent/AU2007315833A1/en not_active Abandoned
- 2007-10-31 HR HR20090470A patent/HRP20090470A2/hr not_active Application Discontinuation
- 2007-10-31 JP JP2009535825A patent/JP2010509310A/ja active Pending
- 2007-10-31 BR BRPI0718391-7A patent/BRPI0718391A2/pt not_active IP Right Cessation
- 2007-10-31 NZ NZ577978A patent/NZ577978A/en unknown
- 2007-10-31 DE DE602007013801T patent/DE602007013801D1/de active Active
- 2007-10-31 NZ NZ577311A patent/NZ577311A/en unknown
- 2007-10-31 KR KR1020097011287A patent/KR20090077014A/ko not_active Withdrawn
- 2007-10-31 EP EP07825550A patent/EP2094675B1/en not_active Not-in-force
- 2007-10-31 US US12/513,352 patent/US20100069451A1/en not_active Abandoned
- 2007-10-31 AT AT07825550T patent/ATE504578T1/de not_active IP Right Cessation
- 2007-10-31 CA CA002667513A patent/CA2667513A1/en not_active Abandoned
- 2007-10-31 RS RSP-2009/0388A patent/RS20090388A/sr unknown
- 2007-10-31 WO PCT/IB2007/003291 patent/WO2008053325A1/en not_active Ceased
-
2009
- 2009-04-28 IL IL198443A patent/IL198443A0/en unknown
- 2009-04-28 IL IL198444A patent/IL198444A0/en unknown
- 2009-05-25 ZA ZA200903618A patent/ZA200903618B/xx unknown
- 2009-05-29 NO NO20092115A patent/NO20092115L/no not_active Application Discontinuation
- 2009-05-29 NO NO20092114A patent/NO20092114L/no not_active Application Discontinuation
- 2009-06-01 ZA ZA200903810A patent/ZA200903810B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2445340B1 (en) | Substituted hydroxamic acids and uses thereof | |
| ES2264060T3 (es) | Derivado de 2-oxo-1-pirrolidina y sus usos farmaceuticos. | |
| KR100523366B1 (ko) | 티에닐아졸일알콕시에탄아민, 이의 제조방법 및 이의 용도 | |
| JP2023508469A (ja) | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 | |
| UA114406C2 (uk) | Похідні циклопропанаміну як інгібітори lsd1 | |
| WO2012012322A1 (en) | Substituted hydroxamic acids and uses thereof | |
| US11078153B2 (en) | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase | |
| RU2009120724A (ru) | Соль 3-бензил-2-метил-2,3,3а,4,5,6,7,7а-октагидробензо[d]изоксазол-4-она | |
| JP6929857B2 (ja) | ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド | |
| TWI235151B (en) | Lactam compound | |
| CN111320625A (zh) | 一种治疗肺炎的化合物及其应用 | |
| MX2012010594A (es) | Hidrato del hidrobromuro de agomelatina y preparacion de este. | |
| US9463187B2 (en) | Methylphenidate derivatives and uses of them | |
| EP2001464A2 (en) | Duloxetine salts | |
| CN116947743B (zh) | 一类亚硝基硫醇化合物及其合成方法、用途 | |
| WO2022074587A1 (en) | Mu-opioid receptor agonists and uses therefor | |
| CN104513172B (zh) | 含有三氟甲基的酰胺生物碱、制备方法及其药物用途 | |
| TW200423924A (en) | Gabapentin analogues for fibromyalgia and other disorders | |
| JPS61500437A (ja) | ｎ−プロパノ−ルアミン誘導体のエ−テル | |
| CA3180417A1 (en) | Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid | |
| RU2465273C2 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| JP4738421B2 (ja) | Ｇｌｙｔ−１阻害剤としてのベンゾイル−テトラヒドロピリジン | |
| EA050094B1 (ru) | Синтез (2s,5r)-5-(2-хлорфенил)-1-(2'-метокси-[1,1'-бифенил]-4-карбонил)пирролидин-2-карбоновой кислоты | |
| WO2025030075A1 (en) | Crystalline hydrochloride and fumarate salts of n-ethyl-2- (5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine | |
| JP5546684B2 (ja) | アミド−トロパン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110922 |